Lineage Cell Therapeutics (LCTX) 10-Q 10 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 04, 2018
Document And Entity Information
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	876,343
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		126,873,240
Trading Symbol	BTX
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 29,827	$ 36,838
Marketable equity securities	1,552	1,337
Trade accounts and grants receivable, net	916	780
Receivable from affiliates, net (Note 9)	2,082	2,266
Prepaid expenses and other current assets	1,749	1,402
Total current assets	36,126	42,623
Property, plant and equipment, net	5,366	5,533
Deposits and other long-term assets	236	1,018
Intangible assets, net	6,317	6,900
TOTAL ASSETS	110,395	173,241
CURRENT LIABILITIES
Accounts payable and accrued liabilities	4,703	5,718
Capital lease and lease liabilities, current portion	222	212
Promissory notes, current portion	120	152
Deferred license and subscription revenues	563	488
Deferred grant revenues	202	309
Total current liabilities	5,810	6,879
LONG-TERM LIABILITIES
Deferred rent liabilities, net of current portion	114	105
Lease liability, net of current portion	968	1,019
Capital lease, net of current portion and other liabilities	122	132
Promissory notes, net of current portion		18
Liability classified warrants and other long-term liabilities	926	825
TOTAL LIABILITIES	7,940	8,978
Commitments and contingencies (Note 13)
SHAREHOLDERS’ EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2018 and December 31, 2017
Common shares, no par value, 150,000 shares authorized (Note 14); 126,869 shares issued and outstanding as of March 31, 2018 and 126,866 shares issued and outstanding as of December 31, 2017	379,186	378,487
Accumulated other comprehensive income	198	451
Accumulated deficit	(279,416)	(216,297)
BioTime, Inc. shareholders’ equity	99,968	162,641
Noncontrolling interest	2,487	1,622
Total shareholders’ equity	102,455	164,263
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	110,395	173,241
OncoCyte Corporation [Member]
CURRENT ASSETS
Equity method investment at fair value	30,816	68,235
Asterias Biotherapeutics [Member]
CURRENT ASSETS
Equity method investment at fair value	$ 31,534	$ 48,932

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock no par value
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	126,869,000	126,866,000
Common stock, shares outstanding	126,869,000	126,866,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
REVENUES:
Grant revenue	$ 326	$ 11	[1]
Royalties from product sales and license fees	136	110	[1]
Subscription and advertisement revenues	239	264	[1]
Sale of research products and services		5	[1]
Total revenues	701	390	[1]
Cost of sales	(109)	(57)
Gross profit	592	333
OPERATING EXPENSES:
Research and development	5,935	6,494
Acquired in-process research and development (Note 9)	800
General and administrative	6,044	5,101
Total operating expenses	12,779	11,595
Loss from operations	(12,187)	(11,262)
OTHER INCOME/(EXPENSES):
Interest income (expense), net	52	(306)
Gain on sale of equity method investment in Ascendance	3,215
Unrealized gain on marketable equity securities	215
Other income (expense), net	(176)	727
Total other income (expenses), net	(51,511)	62,163
INCOME (LOSS) BEFORE INCOME TAXES	(63,698)	50,901
Deferred income tax expense		(3,877)
NET INCOME (LOSS)	(63,698)	47,024
Net loss attributable to noncontrolling interest	150	2,264
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	$ (63,548)	$ 49,288
NET INCOME (LOSS) PER COMMON SHARE:
BASIC	$ (0.50)	$ 0.46
DILUTED	$ (0.50)	$ 0.46
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC	126,869	106,712
DILUTED	126,869	107,384
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain on deconsolidation		$ 71,697
Gain (loss) on equity method investment at fair value	(37,419)	16,142
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment at fair value	$ (17,398)	$ (26,097)
[1]	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
NET INCOME (LOSS)	$ (63,698)	$ 47,024
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment, net of tax	75	847
Available-for-sale investments:
Reclassification of beginning accumulated other comprehensive income to accumulated deficit (Note 2)	(328)
Unrealized gain on available-for-sale securities, net of taxes		299
COMPREHENSIVE INCOME (LOSS)	(63,951)	48,170
Less: Comprehensive loss attributable to noncontrolling interest	150	2,264
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (63,801)	$ 50,434

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to BioTime, Inc.	$ (63,548)	$ 49,288
Net loss allocable to noncontrolling interest	(150)	(2,264)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance	(3,215)
Acquired in-process research and development	800
Unrealized gain on marketable equity securities	(215)
Depreciation expense, including amortization of leasehold improvements	281	216
Amortization of intangible assets	582	602
Stock-based compensation	984	1,026
Liability classified warrants	108
Amortization of discount on related party convertible debt		253
Foreign currency remeasurement and other (gain) loss	87	(829)
Deferred income tax provision		3,877
Changes in operating assets and liabilities:
Accounts and grants receivable, net	(37)	248
Receivables from affiliates, net of payables	175	231
Prepaid expenses and other current assets	(213)	338
Accounts payable and accrued liabilities	(840)	655
Other liabilities	46	3
Net cash used in operating activities	(10,338)	(8,098)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance	3,215
Purchase of in-process research and development	(800)
Purchase of equipment and other assets	(198)	(215)
Security deposit paid	(6)	(41)
Net cash provided by (used in) investing activities	2,211	(9,154)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares		20,125
Fees paid on sale of common shares		(1,345)
Proceeds from exercises of stock options		25
Common shares received and retired for employee taxes paid	(7)
Proceeds from sale of subsidiary warrants	737
Repayment of lease liability and promissory notes	(97)	(31)
Reimbursement from landlord on construction in progress		200
Proceeds from issuance of related party convertible debt		123
Net cash provided by financing activities	633	19,097
Effect of exchange rate changes on cash, cash equivalents and restricted cash	60	(117)
NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(7,434)	1,728
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH:
At beginning of the period	37,685	22,935
At end of the period	30,251	24,663
OncoCyte Corporation [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation		(71,697)
Unrealized (gain) loss on equity method investment in at fair value	37,419	(16,142)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents of OncoCyte		(8,898)
Asterias Biotherapeutics [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Unrealized (gain) loss on equity method investment in at fair value	$ 17,398	$ 26,097

Organization and Business Overv

Organization and Business Overview	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Overview	1. Organization and Business Overview General – HyStem ® HyStem ® BioTime’s lead cell replacement clinical product is OpRegen ® BioTime’s lead cell delivery clinical product, based on its proprietary HyStem ® Renevia ® HyStem ® In 2017, BioTime formed AgeX Therapeutics, Inc. (“AgeX”) development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders. . AgeX may also pursue other early-stage programs. On August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime for use in its research and development programs and raised $10.0 million in cash from investors to finance its operations. This capitalization of AgeX As of March 31, 2018, BioTime owned approximately 85% of the issued and outstanding shares of AgeX common stock (see Note 10). BioTime is also enabling early-stage programs in other new technologies through its own research programs as well as through other subsidiaries or affiliates. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and OncoCyte Corporation (“OncoCyte”), which BioTime founded and, until recently, were majority-owned and consolidated subsidiaries. Asterias (NYSE American: AST) is presently focused on advancing three clinical-stage programs that have the potential to address areas of very high unmet medical needs in the fields of neurology (spinal cord injury) and oncology (Acute Myeloid Leukemia and lung cancer). OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer, and bladder cancer utilizing novel liquid biopsy technology. Beginning on February 17, 2017, BioTime deconsolidated OncoCyte’s financial statements and results of operations from BioTime (the “OncoCyte Deconsolidation”) (see Notes 3 and 4). Beginning on May 13, 2016, BioTime also deconsolidated Asterias’ financial statements and results of operations from BioTime (the “Asterias Deconsolidation”) (see Notes 3 and 5).

Basis of Presentation, Liquidit

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies	2. Basis of Presentation, Liquidity and Summary of Significant Accounting Policies The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2017 was derived from the audited consolidated financial statements at that date, but does not include all the information and footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in BioTime’s Annual Report on Form 10-K for the year ended December 31, 2017. The accompanying interim condensed consolidated financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of BioTime’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Principles of consolidation – Beginning on February 17, 2017 and May 13, 2016, respectively, OncoCyte and Asterias financial statements and results are no longer a part of BioTime’s condensed consolidated financial statements and results. The market value of OncoCyte and Asterias common stock, as of those respective dates, held by BioTime is now reflected on BioTime’s condensed consolidated balance sheet and the subsequent changes consolidated balance sheet and condensed OncoCyte’s results are not included in BioTime’s condensed consolidated statements of operations for the three months ended March 31, 2018. Liquidity – sufficient cash, cash equivalents, and liquidity to carry out BioTime’s current operations through at least twelve months from the issuance date of the condensed consolidated financial statements included in this Report. BioTime also holds shares of Asterias and OncoCyte common stock with a combined market value of $62.3 million at March 31, 2018. Although BioTime has no present plans to liquidate its holdings of Asterias or OncoCyte shares, if BioTime needs near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some, or all, of its Asterias or OncoCyte shares, as necessary. BioTime’s projected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meet future capital needs could force it to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on its evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. For example, clinical trials being conducted for its OpRegen ® OpRegen ® Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method assets which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the condensed consolidated statements of operations in other income and expenses, net. As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP, but continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, BioTime’s value in shares of common stock it holds in Asterias and OncoCyte is marked to market at each balance sheet date using the closing prices of Asterias and OncoCyte common stock on the NYSE American multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the condensed consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures Marketable equity securities in foreign investments Investments – Debt and Equity Securities Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities , On January 1, 2018, in accordance with the adoption of ASU 2016-01, BioTime recorded a cumulative-effect adjustment for these available-for-sale-securities to reclassify the unrealized gain of $328,000 included in consolidated accumulated other comprehensive income to the beginning of the year consolidated accumulated deficit account. For the three months ended March 31, 2018, BioTime recorded an unrealized gain of $215,000 included in other income and expenses, net, due to the increase in fair market value of the marketable equity securities from December 31, 2017 to March 31, 2018. Basic and diluted net income (loss) per share attributable to common shareholders For the three months ended March 31, 2018, there were no potentially dilutive common share equivalents due to the net loss reported for this period presented. The primary components of the weighted average number of potentially dilutive common shares used to compute diluted net income per common share for the three months ended March 31, 2017 were approximately 330,000 shares of treasury stock, and approximately 342,000 restricted stock units and outstanding stock options (see Note 11). The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Stock options 9,243 4,701 Warrants 9,395 9,395 Restricted stock units 56 100 Recently Adopted Accounting Pronouncements Adoption of ASU 2016-18 , Statement of Cash Flows (Topic 230). Statement of Cash Flows (Topic 230): Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet dates that comprise the total of the same such amounts shown in the consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands): March 31, 2018 (unaudited) December 31, 2017 March 31, 2017 (unaudited) December 31, 2016 Cash and cash equivalents $ 29,827 $ 36,838 $ 23,816 $ 22,088 Restricted cash included in prepaid expenses and other current assets (see Note 13) 346 - - - Restricted cash included in deposits and other long-term assets (see Note 13) 78 847 847 847 Total cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows $ 30,251 $ 37,685 $ 24,663 $ 22,935 Adoption of ASU 2014-09 , Revenues from Contracts with Customers (Topic 606). Revenue from Contracts with Customers Revenue Recognition BioTime adopted Topic 606 as of January 1, 2018 using the modified retrospective transition method applied to those contracts which were not completed as of the adoption date. Results for reporting periods beginning on January 1, 2018 and thereafter are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with BioTime’s historic revenue recognition accounting under Topic 605. On January 1, 2018, the adoption and application of Topic 606 resulted in an immaterial cumulative effect adjustment of BioTime’s beginning consolidated accumulated deficit balance. In the applicable paragraphs below, BioTime has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606. Revenue Recognition by Source and Geography Grant Revenues The following table presents BioTime’s consolidated revenues disaggregated by source (in thousands). Three Months Ended March 31, (unaudited) 2018 2017 (1) Grant revenue $ 326 $ 11 Royalties from product sales and license fees 136 110 Subscription and advertisement revenues 239 264 Sale of research products and services - 5 Total revenues $ 701 $ 390 (1) Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method. The following table presents consolidated revenues (in thousands), disaggregated by geography, based on the billing addresses of customers, or in the case of grant revenues based on where the governmental entities that fund the grant are located. See further discussion under Grant Revenues Three Months Ended March 31, (unaudited) 2018 2017 (1) United States $ 507 $ 173 Foreign 194 217 Total revenues $ 701 $ 390 Research and development contracts with customers. Royalties from product sales and license fees. For the three months ended March 31, 2018 and 2017, BioTime recognized $59,000 and $33,000, respectively, in royalty revenues included in consolidated royalties from product sales and license fees. Sale of research products and services. Subscription and advertisement revenues , including research databases and software tools, iomedical, gene, disease, and stem cell research. GeneCards ® GeneCards ® MalaCards LifeMap Sciences’ performance obligations for subscriptions include a license of intellectual property related to its genetic information packages and premium genetic information tools. The licenses for genetic information packages are deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. The license for the premium genetic information tools is a functional license and provides the customer with a “right to use” LifeMap Sciences’ intellectual property and, accordingly, revenue is recognized upfront at the beginning of the subscription period. Payments are typically received at the beginning of a subscription period and revenue is recognized according to the type of subscription sold. Amounts required to be allocated to the premium genetic information tools for immediate recognition is immaterial. For subscription contracts in which the subscription term commences before a payment is due, LifeMap Sciences records an accounts receivable as the subscription is earned over time and bills the customer according to the contract terms. LifeMap Sciences continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the allowance for doubtful accounts. LifeMap Sciences has not historically provided significant discounts, credits, concessions, or other incentives from the stated price in the contract as the prices are offered on a fixed fee basis for the type of subscription package being purchased. LifeMap Sciences may issue refunds only if the packages cease to be available for reasons beyond its control. In such an event, the customer will get a refund on a pro-rata basis. Using the most likely amount method for estimating refunds under Topic 606, including historical experience, LifeMap Sciences determined that the single most likely amount of variable consideration for refunds is immaterial as LifeMap Sciences does not expect to pay any refunds. Both the customer and LifeMap Sciences expect the subscription packages to be available during the entire subscription period, and LifeMap Sciences has not experienced any significant issues with the availability of the product and has not issued any material refunds. LifeMap Sciences performance obligations for advertising are overall advertising services and represent a series of distinct services. Contracts are typically less than a year in duration and the fees charged may include a combination of fixed and variable fees with the variable fees tied to click throughs to the customer’s products on their website. LifeMap Sciences allocates the variable consideration to each month the click through services occur and allocates the annual fee to the performance obligation period of the initial term of the contract because those amounts correspond to the value provided to the customer each month. For click-through advertising services, at the time the variable compensation is known and determinable, the service has been rendered. Revenue is recognized at that time. The annual fee is recognized over the initial subscription period because this is a service and the customer simultaneously receives and consumes the benefit of LifeMap Sciences’ performance. LifeMap Sciences deferred subscription revenues primarily represent subscriptions for which cash payment has been received for the subscription term but the subscription term has not been completed as of the balance sheet date reported. For the three months ended March 31, 2018 and 2017, LifeMap Sciences recognized $239,000 and $264,000 in subscription and advertisement revenues. As of March 31, 2018, there was $330,000 included in deferred revenues in the condensed consolidated balance sheets which is expected to be recognized as subscription revenue over the next twelve months. LifeMap Sciences has licensed from a third party the databases it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs are included in cost of sales on the condensed consolidated statements of operations when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs – Contracts with Customers Grant Revenues Research and Development Arrangements Deferred grant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have not yet been incurred as of the balance sheet date reported. Arrangements with Multiple Performance Obligations Adoption of ASU 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities Changes to the current GAAP model under ASU 2016-01 primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. As further discussed above under the m arketable equity securities in foreign investments policy, BioTime adopted ASU 2016-01 on January 1, 2018. Recently Issued Accounting Pronouncements Not Yet Adopted

Deconsolidation of OncoCyte

Deconsolidation of OncoCyte	3 Months Ended
	Mar. 31, 2018
Deconsolidation of OncoCyte and Asterias [Abstract]
Deconsolidation of OncoCyte	3. Deconsolidation of OncoCyte On February 17, 2017, OncoCyte issued 625,000 shares of OncoCyte common stock to certain investors who exercised OncoCyte stock purchase warrants. As a result of this exercise and the issuance of the shares of OncoCyte common stock, beginning on February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock and experienced a loss of control of the OncoCyte subsidiary. Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of these loss of control factors were present with respect to OncoCyte on February 17, 2017. Accordingly, BioTime has deconsolidated OncoCyte’s financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), Consolidation Beginning on February 17, 2017, BioTime is accounting for its retained noncontrolling investment in OncoCyte under the equity method of accounting and has elected the fair value option under ASC 825-10, Financial Instruments 71.7

Equity Method Accounting for Co

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value	3 Months Ended
	Mar. 31, 2018
Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract]
Equity Method Accounting for Common Stock of OncoCyte, at Fair Value	4 Equity Method Accounting for Common Stock of OncoCyte, at Fair Value BioTime elected to account for its 14.7 million shares of OncoCyte common stock 68.2 million as of December 31, 2017 4.65 For the three months ended March 31, 2017, BioTime recorded an unrealized gain of $16.1 million on the OncoCyte shares due to the increase in OncoCyte’s stock price from February 17, 2017 to March 31, 2017. OncoCyte’s unaudited condensed results of operations for the three months ended March 31, 2018 and 2017 are summarized below (in thousands): Three Months Ended March 31, 2018 (unaudited) February 17, 2017 to March 31, 2017 (unaudited) January 1, 2017 to February 16, 2017 (unaudited) Condensed Statements of Operations (1) Research and development expense $ 1,461 $ 1,049 $ 798 General and administrative expense 1,732 1,651 377 Sales and marketing expense 658 442 213 Loss from operations (3,851 ) (3,142 ) (1,388 ) Net loss $ (3,723 ) $ (3,311 ) $ (1,392 ) (1) The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017 reflects OncoCyte results of operations included in BioTime’s consolidated statement of operations for the three months ended March 31, 2017, after intercompany eliminations. The information for OncoCyte shown for period from February 17, 2017 through March 31, 2017 is not included in BioTime’s consolidated statement of operations for the three months ended March 31, 2017, due to the OncoCyte Deconsolidation on February 17, 2017. The information for OncoCyte shown for three months ended March 31, 2018 is not included in BioTime’s consolidated statement of operations for the three months ended March 31, 2018.

Equity Method Accounting for 11

Equity Method Accounting for Common Stock of Asterias, at Fair Value	3 Months Ended
	Mar. 31, 2018
Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]
Equity Method Accounting for Common Stock of Asterias, at Fair Value	5. Equity Method Accounting for Common Stock of Asterias, at Fair Value BioTime elected to account for its 21.7 million shares of Asterias common stock Asterias’ unaudited condensed results of operations for the three months ended March 31, 2018 and 2017 are summarized below (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Condensed Statements of Operations (1) Total revenue $ 478 $ 2,010 Gross profit 415 1,957 Loss from operations (5,123 ) (9,107 ) Net loss $ (2,312 ) $ (6,287 ) (1) The condensed unaudited statements of operations information included in the table above reflect Asterias’ results of operations and were not included in BioTime’s condensed consolidated statements of operations.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	6. Property, Plant and Equipment, Net At March 31, 2018 and December 31, 2017, property, plant and equipment was comprised of the following (in thousands): March 31, 2018 (unaudited) December 31, 2017 Equipment, furniture and fixtures $ 4,002 $ 4,255 Leasehold improvements 4,069 4,434 Accumulated depreciation and amortization (2,705 ) (3,156 ) Property, plant and equipment, net $ 5,366 $ 5,533 Depreciation expense, including amortization of leasehold improvements, amounted to $281,000 and $216,000 for the three months ended March 31, 2018 and 2017, respectively.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	7. Intangible Assets, Net At March 31, 2018 and December 31, 2017, intangible assets, primarily consisting of acquired patents, and accumulated amortization were as follows (in thousands): March 31, 2018 (unaudited) December 31, 2017 Intangible assets $ 23,294 $ 23,294 Accumulated amortization (16,977 ) (16,394 ) Intangible assets, net $ 6,317 $ 6,900 BioTime recognized $582,000 and $602,000 in amortization expense of intangible assets, included in research and development expenses, during the three months ended March 31, 2018 and 2017, respectively.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	8. Accounts Payable and Accrued Liabilities At March 31, 2018 and December 31, 2017, accounts payable and accrued liabilities consisted of the following (in thousands): March 31, 2018 (unaudited) December 31, 2017 Accounts payable $ 703 $ 938 Accrued liabilities 2,010 2,368 Accrued compensation 1,698 2,275 Other current liabilities 292 137 Total $ 4,703 $ 5,718

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions Shared Facilities and Service Agreements with Affiliates The receivables from affiliates shown on the condensed consolidated balance sheet as of March 31, 2018 and December 31, 2017, primarily represent amounts owed to BioTime from OncoCyte and other affiliates under certain Shared Facilities and Service Agreements (each a “Shared Facilities Agreement”) . Under the terms of a Shared Facilities Agreement, BioTime allows OncoCyte to use BioTime’s premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime also provides accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may provide professional services to BioTime and its other subsidiaries. BioTime also has provided OncoCyte with the services of laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises. BioTime charges OncoCyte a “Use Fee” for services provided and usage of BioTime facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates to OncoCyte costs incurred, including costs for services of Bio Time employees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. The allocation of costs depends on key cost drivers, including actual documented use, square footage of facilities used, time spent, costs incurred by BioTime for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime. BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs. The allocated cost of BioTime employees and contractors who provide services is based upon records of the number of hours of such personnel devoted to the performance of services. The Use Fee is determined and invoiced to OncoCyte on a calendar quarterly basis. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through March 31, 2018, BioTime has not charged OncoCyte any interest. In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers to invoice OncoCyte directly. The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement is otherwise terminated under another provision of the agreement. In the aggregate, BioTime allocated and charged to OncoCyte Use Fees of $171,000 and $79,000 for general and administrative expenses and Use Fees of $220,000 and $317,000 for research and development expenses, during the three months ended March 31, 2018 and 2017, respectively. Those charges to OncoCyte are not reflected in revenues but instead BioTime’s general and administrative expenses and research and development expenses are shown net of those charges in the condensed consolidated statement of operations. As of March 31, 2018 and December 31, 2017, BioTime has a $2.1 million receivable from OncoCyte included in receivable from affiliates, net, on account of Use Fees incurred by OncoCyte under the Shared Facilities Agreement. Since these amounts are due and payable within 30 days of being invoiced, the receivable is classified as a current asset. BioTime has a similar Shared Facilities Agreement with Asterias under which BioTime and Asterias each may provide use of their respective facilities, utilities, and personnel to the other party on terms similar to the terms of the Shared Facilities Agreement between BioTime and OncoCyte. As of , there was a net payable to Asterias of $25,000 and $33,000, respectively. BioTime accounts for receivables from affiliates, net of payables to affiliates, if any, for similar shared services and other transactions BioTime’s consolidated subsidiaries may enter into with nonconsolidated affiliates. BioTime and the affiliates record those receivables and payables on a net basis since BioTime and the affiliates intend to exercise a right of offset of the receivable and the payable and to settle the balances net by having the party that owes the other party pay the net balance owed. Transactions with Ascendance Biotechnology, Inc. On March 21, 2018, AgeX and Ascendance Biotechnology, Inc. (“Ascendance”), an equity method investee of AgeX and former equity method investee of BioTime, entered into an Asset Purchase Agreement (the “Asset Agreement”) in which AgeX purchased for $800,000 in cash certain assets consisting in value primarily of in-process research and development assets related to stem cell derived cardiomyocytes (heart muscle cells) to be developed by AgeX. The transaction was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, Business Combinations Disposition of Ownership Interest in Ascendance On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. AgeX recognized a $3.2 million gain as a sale of its equity method investment in Ascendance, which is included in other income and expenses, net, for the three months ended March 31, 2018. At the close of the merger, $955,000 of cash that otherwise would have been payable to the Ascendance stockholders was deposited into an escrow account where it may be held for a term of up to fifteen months. Funds held in the escrow account may be paid to the acquirer to cover indemnity payments and other obligations that may arise after the merger. After the expiration of the term of the escrow, any funds remaining in the escrow account will be disbursed, on a pro-rata basis, to the former Ascendance stockholders. As of March 31, 2018, no amounts have been recorded in the BioTime consolidated financial statements for any funds held in the escrow account. Other related party transaction In February 2018, Alfred D. Kingsley, the Chairman of BioTime’s Board of Directors, BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Shareholders' Equity	10. Shareholders’ Equity Preferred Shares BioTime is authorized to issue 2,000,000 preferred shares. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. There are no preferred shares issued and outstanding. Common Shares At March 31, 2018, BioTime was authorized to issue 150,000,000 common shares, no par value (see Note 14). As of March 31, 2018, and December 31, 2017, BioTime had 126,869,140 and 126,865,634 issued and outstanding common shares, respectively. On April 6, 2017, BioTime, entered into a Controlled Equity Offering SM BioTime will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreement may be terminated by Cantor Fitzgerald or BioTime at any time upon notice to the other party, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in BioTime’s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. Issuance of Certain Cell Cure Warrants On July 10, 2017, BioTime purchased all of the outstanding Cell Cure convertible promissory notes and Cell Cure ordinary shares held by Hadasit , a former Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares and substantially all of the Cell Cure convertible promissory notes issued by Cell Cure to shareholders other than BioTime Derivatives and Hedging The fair value of the HBL Warrants at the time of issuance was determined by using the Black-Scholes-Merton option pricing model using the contractual term of the HBL Warrants. In applying this model, the fair value is determined by applying Level 3 inputs, as defined by ASC 820; these inputs are based on certain key assumptions including the fair value of the Cell Cure ordinary shares and the expected stock price volatility over the term of the HBL Warrants. The fair value of the Cell Cure ordinary shares is determined by Cell Cure’s Board of Directors, which may engage a valuation specialist to estimate the fair value, or may use recent transactions in Cell Cure shares, if any, as a reasonable approximation of fair value, or may apply other reasonable methods to determining the fair value. BioTime determines the stock price volatility using historical prices of comparable public company common stock for a period equal to the remaining term of the HBL Warrants. The HBL Warrants are revalued each reporting period using the same methodology described above. Changes in any of the key assumptions used to value the HBL Warrants could materially impact the fair value of the HBL Warrants and BioTime’s consolidated financial statements. For the three months ended March 31, 2018, Cell Cure recorded a noncash expense of $79,000 included in general and administrative expenses for the change in fair value of the HBL Warrants liability. As of March 31, 2018 and December 31, 2017, the HBL Warrants, valued at $614,000 and $535,000, respectively, were included in other long-term liabilities on the consolidated balance sheets. Sale of Warrants by AgeX On February 28, 2018, AgeX sold warrants to purchase 1,473,600 shares of AgeX common stock (the “AgeX Warrants”) for $0.50 per warrant for aggregate cash proceeds to AgeX of $736,800. The AgeX Warrants are exercisable at $2.50 per share and expire the earliest to occur of (i) February 28, 2021, (ii) on or after January 31, 2019, after notice from AgeX, if the AgeX shares are publicly traded and the price of AgeX common stock exceeds $3.75 per share for 20 trading days (on a volume weighted average price basis, as defined), and (iii) a change of control, as defined in warrant agreement. If the AgeX shares are not publicly traded, the AgeX Warrants may be exercised only during the period commencing ten business days prior to the expiration date, as defined in the warrant agreement. The AgeX Warrants are classified as equity since, among other factors, they are not redeemable, cannot be settled in cash or other assets and require settlement by issuing a fixed number of shares of common stock of AgeX. The AgeX Warrants were sold at fair value determined on the Binomial Lattice option pricing model on the issuance date, with certain management assumptions, which included the timing of an initial public offering of AgeX common stock, peer-group volatility, term to maturity, price cap and AgeX current and future stock prices.

Stock Option Plans

Stock Option Plans	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plans	11. Stock Option Plans BioTime adopted the 2012 Equity Incentive Plan (the “2012 Plan”), under which a maximum of 16,000,000 BioTime common shares are available for the grant of stock options, restricted stock, restricted stock units and stock appreciation rights. A summary of BioTime’s 2012 Plan activity and related information follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price of Options December 31, 2017 (1) 2,485 8,043 62 $ 3.38 Options granted (1,239 ) 1,239 - 2.58 Options exercised - - - - Options forfeited/cancelled 56 (66 ) - 3.88 Restricted stock units vested - - (6 ) - March 31, 2018 (1) 1,302 9,216 56 3.27 Options exercisable at March 31, 2018 4,615 $ 3.54 (1) On October 13, 2017, BioTime’s Board of Directors (the “Board”) determined to temporarily set a 5.0 million total share limit on shares available for the grant of share-based awards pursuant to the 2012 Plan. As of December 31, 2017, the total 2.5 million shares available for grant was net of this 5.0 million share restriction. On May 4, 2018, the Board removed this restriction, thereby increasing shares available for the grant of share-based awards pursuant to the 2012 Plan to 6.3 million shares as of that date. Stock-Based Compensation Expense The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table Three Months Ended March 31, (unaudited) 2018 2017 Expected life (in years) 5.87 6.08 Risk-free interest rates 2.63 % 2.07 % Volatility 56.09 % 59.83 % Dividend yield - % - % Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Research and development $ 193 $ 331 General and administrative 791 695 Total stock-based compensation expense $ 984 $ 1,026

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting For items that BioTime cannot reliably estimate on an annual basis (principally unrealized gains or losses generated by changes in the market prices of the Asterias and OncoCyte shares BioTime holds), BioTime uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of each item, including the use of all available net operating losses and other credits or deferred tax assets. Although the deconsolidation of Asterias and OncoCyte were not taxable transactions to BioTime and did not create a current income tax payment obligation to BioTime, the market value of the shares of Asterias and OncoCyte common stock BioTime holds creates a deferred tax liability to BioTime based on the closing prices of the shares, less BioTime’s tax basis in the shares. The deferred tax liability generated by the Asterias and OncoCyte shares that BioTime holds as of March 31, 2018 is a source of future taxable income to BioTime, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realization of its deferred tax assets to the extent of the deferred tax liability. On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. For financial reporting purposes, AgeX recognized a $3.2 million gain as a sale of its equity method investment in Ascendance (see Note 9). A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. For federal and state income tax purposes, as a result of the deconsolidation of Asterias and OncoCyte and the deferred tax liabilities generated from the market values of Asterias and OncoCyte shares from the respective deconsolidation dates, including the changes to those deferred tax liabilities due to changes in the Asterias and OncoCyte stock prices, BioTime’s deferred tax assets exceeded its deferred tax liabilities as of March 31, 2018 and December 31, 2017. As a result, BioTime established a full valuation allowance as of March 31, 2018 and December 31, 2017 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Accordingly, BioTime did not record any provision or benefit for income taxes for the three months ended March 31, 2018. As of March 31, 2017, for federal income tax purposes, BioTime’s deferred tax liabilities exceeded its deferred tax assets by $3.9 million and, accordingly, BioTime released its entire valuation allowance and recognized a federal deferred income tax expense of $3.9 million during the three months ended March 31, 2017. For state income tax purposes, BioTime has a full valuation allowance on its state deferred tax assets for all periods presented and, accordingly, no state tax provision or benefit was recorded for any period presented.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Alameda Lease On December 10, 2015, BioTime entered into a lease for 30,795 square feet of office and laboratory space in two buildings located in an office park in Alameda, California (the “Alameda Lease”). The term of the Alameda Lease is seven years and BioTime has an option to renew the term for an additional five years. BioTime moved into the facility and the term of the Alameda Lease commenced effective February 1, 2016. Base rent under the Alameda Lease on February 1, 2018 was $68,673 per month, and will increase by approximately 3% annually on every February 1 thereafter during the lease term. The lease payments allocated to the lease liability for leasehold improvements reimbursed by the landlord are amortized as debt service on that liability over the lease term. In addition to base rent, BioTime will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of those expenses incurred by the landlord. As security for the performance of its obligations under the Alameda Lease, BioTime provided the landlord with an initial security deposit of approximately $847,000, which was reduced by $423,000 on February 1, 2018 pursuant to the lease agreement, and will be further reduced by an additional $346,000 after the first thirty-six months of the lease term, by applying those amounts to future rent payment obligations under the lease, if BioTime is not in default under the Lease. The security deposit amount under the Alameda Lease is considered restricted cash (see Note 2). New York Leased Office Space BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime for use in conducting meetings and other business affairs, on a month-by-month basis, by one of its directors at an amount that approximates his cost. Cell Cure Lease Cell Cure has leased 1,128 square meters (approximately 12,142 square feet) of office and laboratory space in Jerusalem, Israel under a lease that expires between May 30, 2019 and December 31, 2020, with two additional options to extend the lease for 5 years each. Base monthly rent is NIS 63,402 (approximately U.S. $18,247 per month). In addition to base rent, Cell Cure pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. On January 28, 2018, Cell Cure entered into another lease agreement with its current landlord for an additional 934 square meters (approximately 10,054 square feet) of office space in the same facility in Jerusalem, Israel under a lease that expires on December 31, 2025, with two additional options to extend the lease for 5 years each (the “January 2018 Lease”). The January 2018 Lease commenced on April 1, 2018, and includes a leasehold improvement construction allowance of up to NIS 4,000,000 (approximately up to $1.2 million) from the landlord. The leasehold improvements are expected to be completed by September 30, 2018. Combined base rent and construction allowance payments, assuming the full allowance is utilized, for the January 2018 Lease will be NIS 93,470 per month (approximately $27,000 per month) beginning on October 1, 2018. Litigation – General BioTime will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, BioTime will disclose the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts BioTime has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations. Indemnification In the normal course of business, BioTime may provide indemnifications of varying scope under BioTime’s agreements with other companies or consultants, typically BioTime’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of BioTime’s products and services. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services. Other indemnification obligations may arise from agreements disposing of assets. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands for indemnification. BioTime also maintains various liability insurance policies that limit BioTime’s financial exposure. As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded any liabilities for these agreements as of March 31, 2018 and December 31, 2017. Royalty obligations and license fees BioTime and its subsidiaries or affiliates are parties to certain licensing agreements with research institutions, universities and other parties for the rights to use those licenses and other intellectual property in conducting research and development activities. These licensing agreements provide for the payment of royalties by BioTime or the applicable party to the agreement on future product sales, if any. In addition, in order to maintain these licenses and other rights during the product development, BioTime or the applicable party to the contract must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees. Annual minimum maintenance fees are approximately $135,000 to $150,000 per year. The research and development risk for these products is significant. License fees and related expenses under these agreements were immaterial for the periods presented in the consolidated financial statements provided herein. Grants Under the terms of a grant agreement between Cell Cure and Israel Innovation Authority (“IIA”) (formerly the Office of the Chief Scientist of Israel) of the Ministry of Economy and Industry, for the development of OpRegen ® OpRegen ® Accordingly, pursuant to ASC 730-20, the Cell Cure grant is considered a contract to perform research and development services for others and grant revenue will be recognized as the related research and development expenses are incurred (see Note 2). Israeli law pertaining to such government grants contain various conditions, including substantial penalties and restrictions on the transfer of intellectual property, or the manufacture, or both, of products developed under the grant outside of Israel, as defined by the IIA.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On April 5, 2018, ReCyte was awarded a grant of up to approximately $386,000 from the National Institutes of Health (NIH). The NIH grant provides funding for continued development of AgeX’s technologies for treating stroke. The grant funds will be made available by NIH for payment to ReCyte as allowable expenses are incurred. On May 1, 2018, BioTime’s shareholders approved an amendment of its Articles of Incorporation increasing the number of authorized common shares that BioTime may issue from 150,000,000 shares to 250,000,000 shares.

Basis of Presentation, Liquid21

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of consolidation – Beginning on February 17, 2017 and May 13, 2016, respectively, OncoCyte and Asterias financial statements and results are no longer a part of BioTime’s condensed consolidated financial statements and results. The market value of OncoCyte and Asterias common stock, as of those respective dates, held by BioTime is now reflected on BioTime’s condensed consolidated balance sheet and the subsequent changes consolidated balance sheet and condensed OncoCyte’s results are not included in BioTime’s condensed consolidated statements of operations for the three months ended March 31, 2018.
Liquidity	Liquidity – sufficient cash, cash equivalents, and liquidity to carry out BioTime’s current operations through at least twelve months from the issuance date of the condensed consolidated financial statements included in this Report. BioTime also holds shares of Asterias and OncoCyte common stock with a combined market value of $62.3 million at March 31, 2018. Although BioTime has no present plans to liquidate its holdings of Asterias or OncoCyte shares, if BioTime needs near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some, or all, of its Asterias or OncoCyte shares, as necessary. BioTime’s projected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meet future capital needs could force it to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on its evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. For example, clinical trials being conducted for its OpRegen ® OpRegen ®
Equity Method Accounting for Asterias and Oncocyte, at Fair Value	Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method assets which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the condensed consolidated statements of operations in other income and expenses, net. As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP, but continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, BioTime’s value in shares of common stock it holds in Asterias and OncoCyte is marked to market at each balance sheet date using the closing prices of Asterias and OncoCyte common stock on the NYSE American multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the condensed consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures
Marketable Equity Securities in Foreign Investments	Marketable equity securities in foreign investments Investments – Debt and Equity Securities Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities , On January 1, 2018, in accordance with the adoption of ASU 2016-01, BioTime recorded a cumulative-effect adjustment for these available-for-sale-securities to reclassify the unrealized gain of $328,000 included in consolidated accumulated other comprehensive income to the beginning of the year consolidated accumulated deficit account. For the three months ended March 31, 2018, BioTime recorded an unrealized gain of $215,000 included in other income and expenses, net, due to the increase in fair market value of the marketable equity securities from December 31, 2017 to March 31, 2018.
Basic and Diluted Net Income (Loss) Per Share Attributable to Common Shareholders	Basic and diluted net income (loss) per share attributable to common shareholders For the three months ended March 31, 2018, there were no potentially dilutive common share equivalents due to the net loss reported for this period presented. The primary components of the weighted average number of potentially dilutive common shares used to compute diluted net income per common share for the three months ended March 31, 2017 were approximately 330,000 shares of treasury stock, and approximately 342,000 restricted stock units and outstanding stock options (see Note 11). The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Stock options 9,243 4,701 Warrants 9,395 9,395 Restricted stock units 56 100
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Adoption of ASU 2016-18 , Statement of Cash Flows (Topic 230). Statement of Cash Flows (Topic 230): Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet dates that comprise the total of the same such amounts shown in the consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands): March 31, 2018 (unaudited) December 31, 2017 March 31, 2017 (unaudited) December 31, 2016 Cash and cash equivalents $ 29,827 $ 36,838 $ 23,816 $ 22,088 Restricted cash included in prepaid expenses and other current assets (see Note 13) 346 - - - Restricted cash included in deposits and other long-term assets (see Note 13) 78 847 847 847 Total cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows $ 30,251 $ 37,685 $ 24,663 $ 22,935 Adoption of ASU 2014-09 , Revenues from Contracts with Customers (Topic 606). Revenue from Contracts with Customers Revenue Recognition BioTime adopted Topic 606 as of January 1, 2018 using the modified retrospective transition method applied to those contracts which were not completed as of the adoption date. Results for reporting periods beginning on January 1, 2018 and thereafter are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with BioTime’s historic revenue recognition accounting under Topic 605. On January 1, 2018, the adoption and application of Topic 606 resulted in an immaterial cumulative effect adjustment of BioTime’s beginning consolidated accumulated deficit balance. In the applicable paragraphs below, BioTime has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606. Revenue Recognition by Source and Geography Grant Revenues The following table presents BioTime’s consolidated revenues disaggregated by source (in thousands). Three Months Ended March 31, (unaudited) 2018 2017 (1) Grant revenue $ 326 $ 11 Royalties from product sales and license fees 136 110 Subscription and advertisement revenues 239 264 Sale of research products and services - 5 Total revenues $ 701 $ 390 (1) Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method. The following table presents consolidated revenues (in thousands), disaggregated by geography, based on the billing addresses of customers, or in the case of grant revenues based on where the governmental entities that fund the grant are located. See further discussion under Grant Revenues Three Months Ended March 31, (unaudited) 2018 2017 (1) United States $ 507 $ 173 Foreign 194 217 Total revenues $ 701 $ 390 Research and development contracts with customers. Royalties from product sales and license fees. For the three months ended March 31, 2018 and 2017, BioTime recognized $59,000 and $33,000, respectively, in royalty revenues included in consolidated royalties from product sales and license fees. Sale of research products and services. Subscription and advertisement revenues , including research databases and software tools, iomedical, gene, disease, and stem cell research. GeneCards ® GeneCards ® MalaCards LifeMap Sciences’ performance obligations for subscriptions include a license of intellectual property related to its genetic information packages and premium genetic information tools. The licenses for genetic information packages are deemed functional licenses that provide customers with a “right to access” to LifeMap Sciences’ intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. The license for the premium genetic information tools is a functional license and provides the customer with a “right to use” LifeMap Sciences’ intellectual property and, accordingly, revenue is recognized upfront at the beginning of the subscription period. Payments are typically received at the beginning of a subscription period and revenue is recognized according to the type of subscription sold. Amounts required to be allocated to the premium genetic information tools for immediate recognition is immaterial. For subscription contracts in which the subscription term commences before a payment is due, LifeMap Sciences records an accounts receivable as the subscription is earned over time and bills the customer according to the contract terms. LifeMap Sciences continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the allowance for doubtful accounts. LifeMap Sciences has not historically provided significant discounts, credits, concessions, or other incentives from the stated price in the contract as the prices are offered on a fixed fee basis for the type of subscription package being purchased. LifeMap Sciences may issue refunds only if the packages cease to be available for reasons beyond its control. In such an event, the customer will get a refund on a pro-rata basis. Using the most likely amount method for estimating refunds under Topic 606, including historical experience, LifeMap Sciences determined that the single most likely amount of variable consideration for refunds is immaterial as LifeMap Sciences does not expect to pay any refunds. Both the customer and LifeMap Sciences expect the subscription packages to be available during the entire subscription period, and LifeMap Sciences has not experienced any significant issues with the availability of the product and has not issued any material refunds. LifeMap Sciences performance obligations for advertising are overall advertising services and represent a series of distinct services. Contracts are typically less than a year in duration and the fees charged may include a combination of fixed and variable fees with the variable fees tied to click throughs to the customer’s products on their website. LifeMap Sciences allocates the variable consideration to each month the click through services occur and allocates the annual fee to the performance obligation period of the initial term of the contract because those amounts correspond to the value provided to the customer each month. For click-through advertising services, at the time the variable compensation is known and determinable, the service has been rendered. Revenue is recognized at that time. The annual fee is recognized over the initial subscription period because this is a service and the customer simultaneously receives and consumes the benefit of LifeMap Sciences’ performance. LifeMap Sciences deferred subscription revenues primarily represent subscriptions for which cash payment has been received for the subscription term but the subscription term has not been completed as of the balance sheet date reported. For the three months ended March 31, 2018 and 2017, LifeMap Sciences recognized $239,000 and $264,000 in subscription and advertisement revenues. As of March 31, 2018, there was $330,000 included in deferred revenues in the condensed consolidated balance sheets which is expected to be recognized as subscription revenue over the next twelve months. LifeMap Sciences has licensed from a third party the databases it commercializes and has a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs are included in cost of sales on the condensed consolidated statements of operations when the cash is received and the royalty obligation is incurred as the royalty payments do not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs – Contracts with Customers Grant Revenues Research and Development Arrangements Deferred grant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have not yet been incurred as of the balance sheet date reported. Arrangements with Multiple Performance Obligations Adoption of ASU 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities Changes to the current GAAP model under ASU 2016-01 primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. As further discussed above under the m arketable equity securities in foreign investments policy, BioTime adopted ASU 2016-01 on January 1, 2018.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted

Basis of Presentation, Liquid22

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Stock options 9,243 4,701 Warrants 9,395 9,395 Restricted stock units 56 100
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet dates that comprise the total of the same such amounts shown in the consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands): March 31, 2018 (unaudited) December 31, 2017 March 31, 2017 (unaudited) December 31, 2016 Cash and cash equivalents $ 29,827 $ 36,838 $ 23,816 $ 22,088 Restricted cash included in prepaid expenses and other current assets (see Note 13) 346 - - - Restricted cash included in deposits and other long-term assets (see Note 13) 78 847 847 847 Total cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows $ 30,251 $ 37,685 $ 24,663 $ 22,935
Schedule of Disaggregated Revenues	The following table presents BioTime’s consolidated revenues disaggregated by source (in thousands). Three Months Ended March 31, (unaudited) 2018 2017 (1) Grant revenue $ 326 $ 11 Royalties from product sales and license fees 136 110 Subscription and advertisement revenues 239 264 Sale of research products and services - 5 Total revenues $ 701 $ 390 (1) Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
Schedule of Disaggregate by Geographical Revenue	The following table presents consolidated revenues (in thousands), disaggregated by geography, based on the billing addresses of customers, or in the case of grant revenues based on where the governmental entities that fund the grant are located. See further discussion under Grant Revenues Three Months Ended March 31, (unaudited) 2018 2017 (1) United States $ 507 $ 173 Foreign 194 217 Total revenues $ 701 $ 390

Equity Method Accounting for 23

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value (Tables)	3 Months Ended
	Mar. 31, 2018
OncoCyte Corporation [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Condensed Results of Operations and Condensed Balance Sheet Information	OncoCyte’s unaudited condensed results of operations for the three months ended March 31, 2018 and 2017 are summarized below (in thousands): Three Months Ended March 31, 2018 (unaudited) February 17, 2017 to March 31, 2017 (unaudited) January 1, 2017 to February 16, 2017 (unaudited) Condensed Statements of Operations (1) Research and development expense $ 1,461 $ 1,049 $ 798 General and administrative expense 1,732 1,651 377 Sales and marketing expense 658 442 213 Loss from operations (3,851 ) (3,142 ) (1,388 ) Net loss $ (3,723 ) $ (3,311 ) $ (1,392 ) (1) The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017 reflects OncoCyte results of operations included in BioTime’s consolidated statement of operations for the three months ended March 31, 2017, after intercompany eliminations. The information for OncoCyte shown for period from February 17, 2017 through March 31, 2017 is not included in BioTime’s consolidated statement of operations for the three months ended March 31, 2017, due to the OncoCyte Deconsolidation on February 17, 2017. The information for OncoCyte shown for three months ended March 31, 2018 is not included in BioTime’s consolidated statement of operations for the three months ended March 31, 2018.

Equity Method Accounting for 24

Equity Method Accounting for Common Stock of Asterias, at Fair Value (Tables)	3 Months Ended
	Mar. 31, 2018
Asterias Biotherapeutics [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Condensed Results of Operations and Condensed Balance Sheet Information	Asterias’ unaudited condensed results of operations for the three months ended March 31, 2018 and 2017 are summarized below (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Condensed Statements of Operations (1) Total revenue $ 478 $ 2,010 Gross profit 415 1,957 Loss from operations (5,123 ) (9,107 ) Net loss $ (2,312 ) $ (6,287 ) (1) The condensed unaudited statements of operations information included in the table above reflect Asterias’ results of operations and were not included in BioTime’s condensed consolidated statements of operations.

Property, Plant and Equipment25

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	At March 31, 2018 and December 31, 2017, property, plant and equipment was comprised of the following (in thousands): March 31, 2018 (unaudited) December 31, 2017 Equipment, furniture and fixtures $ 4,002 $ 4,255 Leasehold improvements 4,069 4,434 Accumulated depreciation and amortization (2,705 ) (3,156 ) Property, plant and equipment, net $ 5,366 $ 5,533

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	At March 31, 2018 and December 31, 2017, intangible assets, primarily consisting of acquired patents, and accumulated amortization were as follows (in thousands): March 31, 2018 (unaudited) December 31, 2017 Intangible assets $ 23,294 $ 23,294 Accumulated amortization (16,977 ) (16,394 ) Intangible assets, net $ 6,317 $ 6,900

Accounts Payable and Accrued 27

Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	At March 31, 2018 and December 31, 2017, accounts payable and accrued liabilities consisted of the following (in thousands): March 31, 2018 (unaudited) December 31, 2017 Accounts payable $ 703 $ 938 Accrued liabilities 2,010 2,368 Accrued compensation 1,698 2,275 Other current liabilities 292 137 Total $ 4,703 $ 5,718

Stock Option Plans (Tables)

Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity	A summary of BioTime’s 2012 Plan activity and related information follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price of Options December 31, 2017 (1) 2,485 8,043 62 $ 3.38 Options granted (1,239 ) 1,239 - 2.58 Options exercised - - - - Options forfeited/cancelled 56 (66 ) - 3.88 Restricted stock units vested - - (6 ) - March 31, 2018 (1) 1,302 9,216 56 3.27 Options exercisable at March 31, 2018 4,615 $ 3.54 (1) On October 13, 2017, BioTime’s Board of Directors (the “Board”) determined to temporarily set a 5.0 million total share limit on shares available for the grant of share-based awards pursuant to the 2012 Plan. As of December 31, 2017, the total 2.5 million shares available for grant was net of this 5.0 million share restriction. On May 4, 2018, the Board removed this restriction, thereby increasing shares available for the grant of share-based awards pursuant to the 2012 Plan to 6.3 million shares as of that date.
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table Three Months Ended March 31, (unaudited) 2018 2017 Expected life (in years) 5.87 6.08 Risk-free interest rates 2.63 % 2.07 % Volatility 56.09 % 59.83 % Dividend yield - % - %
Schedule of Stock Based Compensation Expense	Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended March 31, (unaudited) 2018 2017 Research and development $ 193 $ 331 General and administrative 791 695 Total stock-based compensation expense $ 984 $ 1,026

Organization and Business Ove29

Organization and Business Overview (Details Narrative) $ in Thousands	Aug. 17, 2017USD ($)	Mar. 31, 2018Sector
Number of platform technologies		2
Number of subsidiaries		2
AgeX Therapeutics, Inc [Member]
Proceeds from sale of common shares of subsidiary | $	$ 10,000
Ownership percentage	85.00%

Basis of Presentation, Liquid30

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Jan. 02, 2018	Mar. 31, 2018	Mar. 31, 2017		Dec. 31, 2017
Accumulated deficit		$ 279,416			$ 216,297
Working capital		30,300
Shareholders' equity		102,455			164,263
Cash, cash equivalents and marketable equity securities		31,400
Unrealized gain/(loss) on available-for-sale securities, net of taxes	$ 328		$ 299
Unrealized gain on marketable equity securities		$ 215
Weighted average dilutive common shares used to compute diluted net income per common share		126,869	107,384
Royalty revenues		$ 136	$ 110	[1]
Subscription and advertisement revenues		239	264	[1]
Research and Development Contracts [Member]
Royalty revenues		77	77
Deferred revenues		231			$ 77
Royalties from Product Sales and License Fees [Member]
Royalty revenues		59	$ 33
Treasury Shares [Member]
Weighted average dilutive common shares used to compute diluted net income per common share			330
Restricted Stock Units and Outstanding Stock Options [Member]
Weighted average dilutive common shares used to compute diluted net income per common share			342
Asterias and OncoCyte [Member]
Common stock combined value		62,300
LifeMap Sciences [Member]
Deferred revenues		330
Subscription and advertisement revenues		$ 239	$ 264
[1]	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.

Basis of Presentation, Liquid31

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount	9,243,000	4,701,000
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	9,395,000	9,395,000
Restricted Stock Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount	56,000	100,000

Basis of Presentation, Liquid32

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 29,827	$ 36,838	$ 24,663	$ 22,935
Restricted cash included in prepaid expenses and other current assets	346
Restricted cash included in deposits and other long-term assets	78	847	847	847
Total cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows	$ 30,251	$ 37,685	$ 24,663	$ 22,935

Basis of Presentation, Liquid33

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	[1]
Accounting Policies [Abstract]
Grant revenue	$ 326	$ 11
Royalties from product sales and license fees	136	110
Subscription and advertisement revenues	239	264
Sale of research products and services		5
Total revenues	$ 701	$ 390
[1]	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.

Basis of Presentation, Liquid34

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Disaggregate by Geographical Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Total revenues	$ 701	$ 390	[1]
United States [Member]
Total revenues	507	173
Foreign [Member]
Total revenues	$ 194	$ 217
[1]	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.

Deconsolidation of OncoCyte (De

Deconsolidation of OncoCyte (Details Narrative) - USD ($) $ in Thousands	Feb. 17, 2017	Mar. 31, 2018	Mar. 31, 2017
Issuance of common stock to certain investors upon exercise of warrants	625,000
OncoCyte Corporation [Member]
Gain on deconsolidation			$ 71,697
Maximum [Member]
Equity method ownership percentage	50.00%

Equity Method Accounting for 36

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value (Details Narrative) - OncoCyte Corporation [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Feb. 17, 2017
Common stock at fair value				14,700,000
Fair value on investment	$ 30,800		$ 68,200
Price per share on NYSE American	$ 2.10		$ 4.65
Unrealized (gain) loss on equity method investment in at fair value	$ 37,419	$ (16,142)

Equity Method Accounting for 37

Equity Method Accounting for Common Stock of OncoCyte, at Fair Value - Schedule of Condensed Results of Operations and Condensed Balance Sheet Information (Details) - OncoCyte Corporation [Member] - USD ($) $ in Thousands		1 Months Ended	2 Months Ended	3 Months Ended
		Mar. 31, 2017	Feb. 16, 2017	Mar. 31, 2018
Research and development expense	[1]	$ 1,049	$ 798	$ 1,461
General and administrative expense	[1]	1,651	377	1,732
Sales and marketing expense	[1]	442	213	658
Loss from operations	[1]	(3,142)	(1,388)	(3,851)
Net loss	[1]	$ (3,311)	$ (1,392)	$ (3,723)
[1]	The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017 reflects OncoCyte results of operations included in BioTime’s consolidated statement of operations for the three months ended March 31, 2017, after intercompany eliminations. The information for OncoCyte shown for period from February 17, 2017 through March 31, 2017 is not included in BioTime’s consolidated statement of operations for the three months ended March 31, 2017, due to the OncoCyte Deconsolidation on February 17, 2017. The information for OncoCyte shown for three months ended March 31, 2018 is not included in BioTime’s consolidated statement of operations for the three months ended March 31, 2018.

Equity Method Accounting for 38

Equity Method Accounting for Common Stock of Asterias, at Fair Value (Details Narrative) - Asterias Biotherapeutics [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	May 13, 2016
Common stock, outstanding				21,700,000
Fair value on investment	$ 31,500		$ 48,900
Price per share on NYSE American	$ 1.45		$ 2.25
Unrealized (gain) loss on equity method investment in at fair value	$ 17,398	$ 26,097

Equity Method Accounting for 39

Equity Method Accounting for Common Stock of Asterias, at Fair Value - Schedule of Condensed Results of Operations and Condensed Balance Sheet Information (Details) - Asterias Biotherapeutics [Member] - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Total revenue	[1]	$ 478	$ 2,010
Gross profit	[1]	415	1,957
Loss from operations	[1]	(5,123)	(9,107)
Net loss	[1]	$ (2,312)	$ (6,287)
[1]	The condensed unaudited statements of operations information included in the table above reflect Asterias’ results of operations and were not included in BioTime’s condensed consolidated statements of operations.

Property, Plant and Equipment40

Property, Plant and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 281	$ 216

Property, Plant and Equipment41

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization	$ (2,705)	$ (3,156)
Property, plant and equipment, net	5,366	5,533
Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	4,002	4,255
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 4,069	$ 4,434

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 582	$ 602

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets	$ 23,294	$ 23,294
Accumulated amortization	(16,977)	(16,394)
Intangible assets, net	$ 6,317	$ 6,900

Accounts Payable and Accrued 44

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts payable	$ 703	$ 938
Accrued liabilities	2,010	2,368
Accrued compensation	1,698	2,275
Other current liabilities	292	137
Total	$ 4,703	$ 5,718

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Mar. 23, 2018USD ($)	Mar. 21, 2018USD ($)	Feb. 28, 2018USD ($)ft²$ / sharesshares	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Receivables from related party					$ 2,100,000
Ascendance Stockholders [Member]
Due to related party				$ 955,000
AgeX Therapeutics [Member]
Gain of sale of equity method investment				$ 3,200,000
AgeX Therapeutics [Member] | Alfred D. Kingsley [Member]
Purchases of warrants | shares			248,600
Stock price per share | $ / shares			$ 2.50
Proceeds from warrants			$ 124,300
Warrant exercise price | $ / shares			$ 0.50
Rent per month			$ 5,050
Area of office space square feet | ft²			900
AgeX Therapeutics [Member] | Third Party [Member]
Proceeds from common stock	$ 3,200,000
Asset Purchase Agreement [Member] | AgeX Therapeutics [Member]
Repayments of related party debt		$ 800,000
OncoCyte Corporation [Member]
Markup rate on allocated costs				5.00%
Interest rate charged on unpaid and overdue invoices				15.00%
OncoCyte Corporation [Member] | General and Administrative Expense [Member]
Fees amount				$ 171,000	79,000
OncoCyte Corporation [Member] | Research and Development Expense [Member]
Fees amount				$ 220,000	$ 317,000
OncoCyte Corporation [Member] | Maximum [Member]
Term of payment				30 days
Asterias Biotherapeutics [Member]
Net payables to related party				$ 25,000		$ 33,000
Ascendance Biotechnology, Inc [Member]
Receivables from related party		200,000
Business combination transaction for related cost		$ 800,000

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Feb. 28, 2018	Jul. 10, 2017	Mar. 31, 2018	Dec. 31, 2017	Apr. 06, 2017
Preferred shares, shares authorized			2,000,000	2,000,000
Preferred shares, shares issued
Preferred shares, shares outstanding
Common stock, shares authorized			150,000,000	150,000,000
Common stock, no par value
Common stock, issued			126,869,000	126,866,000
Common stock, outstanding			126,869,000	126,866,000
Fair value available for grant			$ 24,200,000
Noncash expense			$ 984,000
Cantor Fitzgerald & Co [Member]
Common stock, no par value
Aggregate offering price					$ 25,000,000
Percentage of commission payable			3.00%
HBL Warrants [Member]
Noncash expense			$ 79,000
Warrant value			$ 614,000	$ 535,000
Age X Warrants [Member]
Warrants issued to purchase ordinary shares	1,473,600
Warrants exercise price per share	$ 0.50
Warrants exercisable per share	$ 2.50
Proceeds from warrants	$ 736,800
Warrant expiration term description	The AgeX Warrants are exercisable at $2.50 per share and expire the earliest to occur of (i) February 28, 2021, (ii) on or after January 31, 2019, after notice from AgeX, if the AgeX shares are publicly traded and the price of AgeX common stock exceeds $3.75 per share for 20 trading days (on a volume weighted average price basis, as defined)
Age X Warrants [Member] | Maximum [Member]
Number of common stock issued price per share	$ 3.75
Hadasit Bio-Holdings, Ltd [Member]
Ownership percentage, noncontrolling owners		21.20%
Warrants issued to purchase ordinary shares		24,566
Warrants exercise price per share		$ 40.5359
Warrants exercisable term		5 years

Stock Option Plans (Details Nar

Stock Option Plans (Details Narrative)	Mar. 31, 2018shares
2012 Equity Incentive Plan [Member] | Maximum [Member]
Number of shares available for grant	16,000,000

Stock Option Plans - Schedule o

Stock Option Plans - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) - 2012 Equity Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance	2,485	[1]
Shares Available for Grant, Options Granted	(1,239)
Shares Available for Grant, Options Exercised
Shares Available for Grant Options Forfeited/cancelled	56
Shares Available for Grant Restricted stock units vested
Shares Available for Grant End of the period	1,302	[1]
Number of Options Outstanding, Beginning balance	8,043	[1]
Number of Options Outstanding, Options granted	1,239
Number of Options Outstanding, Options exercised
Number of Options Outstanding, Options forfeited/cancelled	(66)
Number of Options Outstanding, Restricted stock units vested
Number of Options Outstanding, End balance	9,216	[1]
Number of Options Outstanding, Exercisable End of the period	4,615
Number of RSUs Outstanding, Beginning balance	62	[1]
Number of RSUs Outstanding, Restricted stock units vested	(6)
Number of RSUs Outstanding, End balance	56	[1]
Weighted Average Exercise Price of Options Outstanding, beginning balance | $ / shares	$ 3.38	[1]
Weighted Average Exercise Price of Options, Options granted | $ / shares	2.58
Weighted Average Exercise Price of Options, Options exercised | $ / shares
Weighted Average Exercise Price of Options, Options forfeited/cancelled | $ / shares	3.88
Weighted Average Exercise Price of Options, Restricted stock units vested | $ / shares
Weighted Average Exercise Price of Options, Outstanding end balance | $ / shares	3.27	[1]
Weighted Average Exercise Price of Options, Exercisable End of the period | $ / shares	$ 3.54
[1]	On October 13, 2017, BioTime's Board of Directors (the "Board") determined to temporarily set a 5.0 million total share limit on shares available for the grant of share-based awards pursuant to the 2012 Plan. As of December 31, 2017, the total 2.5 million shares available for grant was net of this 5.0 million share restriction. On May 4, 2018, the Board removed this restriction, thereby increasing shares available for the grant of share-based awards pursuant to the 2012 Plan to 6.3 million shares as of that date.

Stock Option Plans - Schedule49

Stock Option Plans - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) (Parenthetical) - Stock Option Plan Of 2012 [Member] - shares	Dec. 31, 2017	Mar. 31, 2018	Oct. 31, 2017
Number of shares available for grant	2,500,000
Number of shares repurchased	5,000,000
May 4, 2018 [Member]
Number of shares available for grant		6,300,000
Board of Directors [Member]
Number of shares available for grant			5,000,000

Stock Option Plans - Schedule50

Stock Option Plans - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected life (in years)	5 years 10 months 14 days	6 years 29 days
Risk-free interest rates	2.63%	2.07%
Volatility	56.09%	59.83%
Dividend yield	0.00%	0.00%

Stock Option Plans - Schedule51

Stock Option Plans - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 984	$ 1,026
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	193	331
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 791	$ 695

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	Mar. 23, 2018	Mar. 31, 2018	Mar. 31, 2017
Proceeds from issuance of common stock			$ 20,125
Deferred tax liabilities			3,900
Deferred income tax expense (benefit), federal			$ 3,900
AgeX Therapeutics [Member]
Proceeds from issuance of common stock	$ 3,200
Gain on sale of equity method investment	3,200
Taxable gain	$ 2,200

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Jan. 28, 2018USD ($)ft²	Dec. 10, 2015ft²Integer	Mar. 31, 2018USD ($)ft²	Feb. 01, 2018USD ($)
Operating Leased Assets [Line Items]
Base rent	$ 27,000
Minimum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees			$ 135,000
Maximum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees			150,000
NIS [Member]
Operating Leased Assets [Line Items]
Base rent	$ 93,470
Cell Cure [Member]
Operating Leased Assets [Line Items]
Leased area | ft²	934
Area of land | ft²	10,054
Alameda Lease [Member]
Operating Leased Assets [Line Items]
Leased area | ft²		30,795
Number of buildings for lease | Integer		2
Lease term		7 years
Number of years lease can be extended		5 years
Lease commencement date		Feb. 1, 2016
Base rent				$ 68,673
Base rent increase rate				3.00%
Security deposit				$ 847,000
Security deposit reduction in value after first twenty four months of lease term				423,000
Additional reduction in value after first thirty six months of lease term				$ 346,000
Reporting Entities [Member] | Office Space in New York City [Member]
Operating Leased Assets [Line Items]
Base rent			$ 5,050
Area of land | ft²			900
Office and Laboratory Space, Jerusalem, Israel [Member]
Operating Leased Assets [Line Items]
Base rent			$ 18,247
Office and Laboratory Space, Jerusalem, Israel [Member] | April 1, 2018 [Member]
Operating Leased Assets [Line Items]
Lease expiration	The leasehold improvements are expected to be completed by September 30, 2018
Construction allowances of leasehold improvements	$ 1,200,000
Office and Laboratory Space, Jerusalem, Israel [Member] | NIS [Member]
Operating Leased Assets [Line Items]
Base rent			$ 63,402
Office and Laboratory Space, Jerusalem, Israel [Member] | NIS [Member] | April 1, 2018 [Member]
Operating Leased Assets [Line Items]
Construction allowances of leasehold improvements	$ 4,000,000
Office and Laboratory Space, Jerusalem, Israel [Member] | Cell Cure [Member]
Operating Leased Assets [Line Items]
Leased area | ft²			1,128
Number of years lease can be extended	5 years		5 years
Area of land | ft²			12,142
Lease expiration	lease that expires on December 31, 2025		a lease that expires between May 30, 2019 and December 31, 2020

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands	May 01, 2018	Apr. 05, 2018	Mar. 31, 2018	Dec. 31, 2017
Common stock, shares authorized			150,000,000	150,000,000
Subsequent Event [Member] | Maximum [Member]
Fair value of grant awarded		$ 386
Common stock, shares authorized	250,000,000
Subsequent Event [Member] | Minimum [Member]
Common stock, shares authorized	150,000,000